Tazeen Ahmad
Stock Analyst at B of A Securities
(3.39)
# 1,005
Out of 5,113 analysts
216
Total ratings
48.72%
Success rate
3.81%
Average return
Main Sectors:
Stocks Rated by Tazeen Ahmad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Initiates: Buy | $195 | $167.34 | +16.53% | 1 | Jan 26, 2026 | |
| APLS Apellis Pharmaceuticals | Upgrades: Buy | $28 | $21.81 | +28.38% | 10 | Jan 21, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $530 → $529 | $354.75 | +49.12% | 6 | Jan 12, 2026 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Buy | $627 → $860 | $771.25 | +11.51% | 1 | Jan 7, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $72 → $58 | $24.62 | +135.58% | 7 | Jan 2, 2026 | |
| FULC Fulcrum Therapeutics | Maintains: Underperform | $6 → $7 | $10.94 | -36.01% | 7 | Dec 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $71 → $112 | $72.15 | +55.23% | 1 | Dec 9, 2025 | |
| PHVS Pharvaris | Maintains: Neutral | $27 → $30 | $27.18 | +10.38% | 5 | Dec 4, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Buy | $53 | $43.99 | +20.48% | 1 | Oct 9, 2025 | |
| INCY Incyte | Maintains: Buy | $90 → $104 | $103.47 | +0.51% | 6 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $227 → $230 | $238.80 | -3.69% | 11 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $880 → $887 | $865.23 | +2.52% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $16 | $22.17 | -27.83% | 26 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $76 | $75.49 | +0.68% | 19 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $27 | $26.20 | +3.05% | 16 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $126 → $134 | $119.34 | +12.28% | 9 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $4.76 | +68.07% | 1 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $95 | $105.53 | -9.98% | 9 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $6.76 | +121.89% | 12 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $22 → $4 | $9.73 | -58.89% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $16.62 | -51.87% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $27 | $21.25 | +27.06% | 3 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $28 | $13.62 | +105.58% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $40 | $8.49 | +371.14% | 4 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $184 → $179 | $133.89 | +33.69% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $14.94 | +47.26% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 → $3 | $5.60 | -46.43% | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $14.29 | +4.97% | 5 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $6.57 | +52.21% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $2 → $6 | $1.31 | +358.02% | 2 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $10.85 | +38.25% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $2 | $3.59 | -44.29% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $6 | $2.12 | +183.02% | 4 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $75 → $15 | $23.03 | -34.87% | 3 | Nov 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $390 → $60 | $314.75 | -80.94% | 2 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $16 | $1.64 | +875.61% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $164.63 | - | 4 | Apr 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $330 → $300 | $24.44 | +1,127.50% | 1 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $19 → $9 | $2.37 | +279.75% | 2 | Oct 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $48 | $19.85 | +141.81% | 6 | Oct 10, 2018 |
Belite Bio
Jan 26, 2026
Initiates: Buy
Price Target: $195
Current: $167.34
Upside: +16.53%
Apellis Pharmaceuticals
Jan 21, 2026
Upgrades: Buy
Price Target: $28
Current: $21.81
Upside: +28.38%
Alnylam Pharmaceuticals
Jan 12, 2026
Maintains: Buy
Price Target: $530 → $529
Current: $354.75
Upside: +49.12%
Regeneron Pharmaceuticals
Jan 7, 2026
Upgrades: Buy
Price Target: $627 → $860
Current: $771.25
Upside: +11.51%
Ultragenyx Pharmaceutical
Jan 2, 2026
Maintains: Buy
Price Target: $72 → $58
Current: $24.62
Upside: +135.58%
Fulcrum Therapeutics
Dec 9, 2025
Maintains: Underperform
Price Target: $6 → $7
Current: $10.94
Upside: -36.01%
Kymera Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $71 → $112
Current: $72.15
Upside: +55.23%
Pharvaris
Dec 4, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $27.18
Upside: +10.38%
Scholar Rock Holding
Oct 9, 2025
Initiates: Buy
Price Target: $53
Current: $43.99
Upside: +20.48%
Incyte
Sep 4, 2025
Maintains: Buy
Price Target: $90 → $104
Current: $103.47
Upside: +0.51%
Sep 2, 2025
Maintains: Buy
Price Target: $227 → $230
Current: $238.80
Upside: -3.69%
Sep 2, 2025
Maintains: Buy
Price Target: $880 → $887
Current: $865.23
Upside: +2.52%
Aug 21, 2025
Maintains: Underperform
Price Target: $17 → $16
Current: $22.17
Upside: -27.83%
Aug 20, 2025
Maintains: Buy
Price Target: $82 → $76
Current: $75.49
Upside: +0.68%
Aug 7, 2025
Maintains: Neutral
Price Target: $23 → $27
Current: $26.20
Upside: +3.05%
Aug 5, 2025
Maintains: Buy
Price Target: $126 → $134
Current: $119.34
Upside: +12.28%
Jul 11, 2025
Initiates: Buy
Price Target: $8
Current: $4.76
Upside: +68.07%
Jul 10, 2025
Maintains: Buy
Price Target: $73 → $95
Current: $105.53
Upside: -9.98%
Jul 1, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $6.76
Upside: +121.89%
May 28, 2025
Downgrades: Underperform
Price Target: $22 → $4
Current: $9.73
Upside: -58.89%
May 19, 2025
Maintains: Underperform
Price Target: $10 → $8
Current: $16.62
Upside: -51.87%
May 19, 2025
Maintains: Buy
Price Target: $28 → $27
Current: $21.25
Upside: +27.06%
Mar 12, 2025
Maintains: Buy
Price Target: $54 → $28
Current: $13.62
Upside: +105.58%
Mar 10, 2025
Maintains: Buy
Price Target: $42 → $40
Current: $8.49
Upside: +371.14%
Feb 7, 2025
Maintains: Buy
Price Target: $184 → $179
Current: $133.89
Upside: +33.69%
Dec 18, 2024
Initiates: Buy
Price Target: $22
Current: $14.94
Upside: +47.26%
Dec 16, 2024
Downgrades: Underperform
Price Target: $6 → $3
Current: $5.60
Upside: -46.43%
Oct 17, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $14.29
Upside: +4.97%
Mar 28, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $6.57
Upside: +52.21%
Mar 28, 2024
Maintains: Underperform
Price Target: $2 → $6
Current: $1.31
Upside: +358.02%
Feb 9, 2024
Initiates: Buy
Price Target: $15
Current: $10.85
Upside: +38.25%
Apr 24, 2023
Downgrades: Underperform
Price Target: $7 → $2
Current: $3.59
Upside: -44.29%
Nov 21, 2022
Downgrades: Underperform
Price Target: $6
Current: $2.12
Upside: +183.02%
Nov 17, 2022
Downgrades: Underperform
Price Target: $75 → $15
Current: $23.03
Upside: -34.87%
Jun 7, 2022
Downgrades: Neutral
Price Target: $390 → $60
Current: $314.75
Upside: -80.94%
Nov 2, 2021
Initiates: Neutral
Price Target: $16
Current: $1.64
Upside: +875.61%
Apr 25, 2019
Downgrades: Underperform
Price Target: n/a
Current: $164.63
Upside: -
Nov 2, 2018
Maintains: Buy
Price Target: $330 → $300
Current: $24.44
Upside: +1,127.50%
Oct 16, 2018
Downgrades: Underperform
Price Target: $19 → $9
Current: $2.37
Upside: +279.75%
Oct 10, 2018
Maintains: Neutral
Price Target: $46 → $48
Current: $19.85
Upside: +141.81%